Study Title
DCL-17-001: A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors, Lymphoma, and Malignant Brain Tumors
Protocol ID
DCL-17-001
Disease (Sub Disease)
Pediatric Solid Tumor
Pediatric Lymphoma
Pediatric Brain Tumor
DIPG
Neuroblastoma
Ewing Sarcoma
Rhabdomyosarcoma
Osteosarcoma
Pediatric Lymphoma
Pediatric Brain Tumor
DIPG
Neuroblastoma
Ewing Sarcoma
Rhabdomyosarcoma
Osteosarcoma
Diagnosis Stage
Relapsed
Refractory
Recurrent
Refractory
Recurrent
Sponsor
Cellectar Biosciences, Inc.
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 1
Age Eligibility
2 Years to 25 Years
International registry ID's
NCT03478462
| Study Title | DCL-17-001: A Phase 1 Open-Label Dose Escalation Study of CLR 131 in Children and Adolescents with Select Solid Tumors Lymphoma and Malignant Brain Tumors |
|---|---|
| Protocol ID | DCL-17-001 |
| Disease (Sub Disease) | Pediatric Solid Tumor Pediatric Lymphoma Pediatric Brain Tumor DIPG Neuroblastoma Ewing Sarcoma Rhabdomyosarcoma Osteosarcoma |
| Diagnosis Stage | Relapsed Refractory Recurrent |
| Sponsor | Cellectar Biosciences, Inc. |
| Links | https://clinicaltrials.gov/ct2/show/NCT03478462 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 30/04/2019 |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 2 Years to 25 Years |
| International registry ID's | NCT03478462 |